BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Edward Morrow Atkinson III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently sold a significant portion of his holdings in the ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 3.14% to $455.22 Tuesday, on what proved to be an all-around favorable ...

The EV maker's investors have to weigh what CEO Elon Musk’s bid to gain control of the ChatGPT creator means for his time and ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Despite slow sales, the housing market had signs of life in the fourth quarter. That could help the home listings site’s ...

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...